RVMD NASDAQ
Revolution Medicines, Inc.
1W: -5.3%
1M: -7.7%
3M: +2.9%
YTD: +135.7%
1Y: +241.8%
3Y: +565.8%
5Y: +577.7%
$186.22
+2.32 (+1.26%)
Weekly Expected Move ±7.2%
$160
$174
$187
$201
$214
Credit Risk of going bust: lower than 73% of companies Debt: 1.6% of company value Bonds: $112.0M held by 36 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.29 (down 99.8%), Revolution Medicines, Inc. would be worth roughly what it owes.
Total debt $641.9M against a stock market value of $39.91B.
Distance to default 8.08 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $243.7M (short-term plus half of long-term), stock volatility 61.7%; Altman Z'' 1.52. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.29 (down 99.8%), Revolution Medicines, Inc. would be worth roughly what it owes.
Total debt $641.9M against a stock market value of $39.91B.
Distance to default 8.08 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $243.7M (short-term plus half of long-term), stock volatility 61.7%; Altman Z'' 1.52. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.45
Bullish
1 bullish
1 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?
Brookline Capital Markets Estimates RVMD Q3 Earnings
7,403 Shares in Revolution Medicines, Inc. $RVMD Purchased by SteelPeak Wealth LLC
3,373 Shares of Revolution Medicines, Inc. $RVMD Bought by First Citizens Bank & Trust Co.
Lilly, Pfizer, J&J among winners of EU drug recommendations this month
Revolution Medicines, Inc. $RVMD Stock Acquired by Assenagon Asset Management S.A.
These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead
Revolution Medicines' Rasonque gains positive CHMP opinion
Revolution Medicines, Inc. (NASDAQ:RVMD) Stock Has Average Target Price of $234.76 According to Analysts
Roche taps Chinese startup for drug discovery
2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
Revolution Medicines (NASDAQ: RVMD) CDO sells 6,309 shares under preset plan
Revolution Medicines (NASDAQ:RVMD) Stock: Insider Elizabeth Anderson Sells 10,143 Shares
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
44,928 Shares in Revolution Medicines, Inc. $RVMD Acquired by Nykredit A S
Alan Sandler Sells 341 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Jack Anders Sells 4,053 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Margaret Horn Sells 4,967 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Stephen Michael Kelsey Sells 5,569 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Engineers Gate Manager LP Buys 4,356 Shares of Revolution Medicines, Inc. $RVMD
983,911 Shares in Revolution Medicines, Inc. $RVMD Bought by Bank of America Corp DE
10 large and mega-cap U.S. healthcare stocks with the strongest momentum grades
These large-cap U.S. stocks have the strongest momentum grades
Stephen Michael Kelsey Sells 92,531 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
Concurrent Investment Advisors LLC Invests $475,000 in Revolution Medicines, Inc. $RVMD
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Director Sells $3,585,823.80 in Stock
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Revolution a new overweight at Morgan Stanley on RAS-targeted oncology franchise
Revolution Medicines, Inc. $RVMD Shares Bought by Arizona State Retirement System
Hsbc Holdings PLC Acquires 39,025 Shares of Revolution Medicines, Inc. $RVMD
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
Revolution Medicines Got Its Breakthrough—What Moves It Next?
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
White House is said to announce drug pricing deals with biotechs
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?
GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity
Biotech Breakout: What's in focus after Moderna's cancer win?
Meet the Vanguard ETF That's Crushing the S&P 500 and Nasdaq-100 Despite Not Owning Micron, Sandisk, or Any of the "Magnificent Seven" Stocks
Corcept, Revolution Medicines lead ten large-cap healthcare stocks surging in 2026
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High – Should You Buy?
Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Amundi Buys 118,493 Shares of Revolution Medicines, Inc. $RVMD
First Trust Advisors LP Boosts Holdings in Revolution Medicines, Inc. $RVMD
Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?
Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock
15,000 Shares in Revolution Medicines, Inc. $RVMD Bought by Avidity Partners Management LP
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
Andra AP fonden Buys Shares of 16,600 Revolution Medicines, Inc. $RVMD
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
Revolution Medicines, Inc. $RVMD Shares Sold by California Public Employees Retirement System
Bessemer Group Inc. Sells 69,600 Shares of Revolution Medicines, Inc. $RVMD
This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It
Better Growth Buy: Axsome vs Revolution Medicines
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
Biotech breakout: iShares Biotechnology ETF hits all-time high
Can Revolution Medicines Be a Game-Changer Stock?
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs
Revolution Medicines reports Phase 3 win in pancreatic cancer
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
Top Research Reports for Home Depot, TJX & Marvell Technology
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
Revolution Medicines outlines $1.7B-$1.8B in 2026 GAAP operating expenses while expanding RASolve 301 to 590 patients
Revolution (RVMD) Q1 2026 Earnings Transcript
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Earnings Scheduled For May 6, 2026
[10-Q] Revolution Medicines, Inc. Quarterly Earnings Report - Stock Titan
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?
Organon & Co is the best performing healthcare stock in April
Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity
Revolution Medicines wins FDA nod to provide early access to cancer therapy
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
Stock Market Today: S&P 500 Drops Amid Tech Sell-Off, Oil Climbs To $100 On Hormuz Drama
Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday?
Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy
Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth
Calamos Advisors LLC Takes $992,000 Position in Revolution Medicines, Inc. $RVMD
12 Health Care Stocks Moving In Monday's After-Market Session